Institutional investors purchased a net $1.8 million shares of PGNX during the quarter ended December 2016 and now own 84.18% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
EAGLE ASSET MANAGEMENT, INC. Bought 2.7 Million shares of Progenics Pharmaceuticals...
PARK WEST ASSET MANAGEMENT LLC Bought 690.4 Thousand shares of Progenics Pharmaceuticals...